
Sign up to save your podcasts
Or


Dr. Jennifer Lyerly walks through the STAR study numbers, the parents who just want the glasses, and the 25-year-old nobody knows what to do with.
Join Us on Substack: full podcast + articles + bonus content
myopiamindset.substack.com
Subscribe on Substack: Weekly podcast + article + bonus content ↓ https://myopiamindset.substack.com
Dr. Carrie Hartigan on building a pediatric-only practice, training a myopia coordinator, winning pediatrician referrals, and why one flat fee changed how she treats every kid.
ABOUT THE SHOW
The Myopia Mindset — conversations with the optometrists and myopia specialists figuring this out in real time. Full episode: https://myopiamindset.substack.com
Dr. David Ng was a happy general practice OD in 2002. Then he put a retinoscope in front of his three-year-old son.
SUBSCRIBE ON OUR SUBSTACK
https://myopiamindset.substack.com/
New episode alerts in your inbox, early episodes, video podcasts, newsletter, and bonus content you wont find anywhere else!
Welcome back to Myopia News Monthly, our ongoing segment where we grab the biggest stories in myopia management and actually break them down.
Get the full episode, details, video and bonus content on our Substack: https://myopiamindset.substack.com/p/ama-myopia-disease-resolution
The FDA just gave myopia management a second chance.
Last October, Sydnexis’ SYD-101 — the low-dose atropine drop that would be the first FDA-approved pharmaceutical treatment for pediatric progressive myopia — was rejected in a Complete Response Letter that left most of us scratching our heads. The Phase 3 STAR trial was the largest pediatric myopia program ever completed (847 children, ages 3–14), the data looked sound, and the FDA’s reasoning never really came.
Now, after Sydnexis filed a formal dispute, the FDA has announced it will convene an advisory committee to review the application. It’s a redo — and this time, the people in the room will actually know myopia.
To unpack what that means, I brought back my regular guest contributor (and dad), Dr. Cary Herzberg — pioneer of myopia management with 40+ years in practice.
SUBSCRIBE on SUBSTACK for early episodes, weekly newsletter, bonus content: https://myopiamindset.substack.com/
He inherited a handful of poorly-fit ortho-K patients, gave himself six months to master the specialty, and ended up co-founding a lens design company. Dr. Sukh Gill returns for a deep-dive interview.
SUBSCRIBE on SUBSTACK for weekly articles, bonus content, and video podcast episodes. https://myopiamindset.substack.com/
Here’s a question Dr. Cary Herzberg wants every optometrist to ask in the mirror: if you dropped every vision care plan tomorrow, could your practice survive?
For most young ODs, the honest answer is no. Not because they aren’t great clinicians — optometry school made sure of that — but because, as Cary puts it, “they don’t teach you how to make a living.”
Cary has spent 50+ years in myopia management, pioneered modern ortho-k, and mentored countless successful specialty docs. Together we’re mapping out how the modern OD can take back control of how they practice and do business — starting with step one: becoming the decision maker.
Subscribe on our substack to further explore how optometrists can reclaim control of their careers in a profession increasingly shaped by vision plans, online retailers, private equity, and high patient volumes. Cary Herzberg argues that becoming the "decision maker" doesn't require owning a practice—it requires taking ownership of the value you bring, whether you're an associate or practicing in a corporate setting. We discuss why informing patients about myopia management isn't "selling," but a professional responsibility, and how today's concerns over children's screen time create an opportunity for optometrists to become trusted advocates for families. Cary outlines a five-step framework for building a fulfilling, specialty-driven career: redefine your professional identity, embrace patient education, choose a specialty, create long-term care plans, and make a compelling business case for the resources you need. The reward is greater professional autonomy, a loyal patient base built on relationships rather than insurance plans, and the freedom to practice on your own terms.
This month’s Myopia News Monthly brings Dr. Andrew Brauer and Dr. Priscilla Chang to the table for three stories — and one genuine disagreement.
SUBSCRIBE ON SUBSTACK
Get the rundown, links to articles, weekly newsletter, bonus content, and the video version of every podcast.
https://myopiamindset.substack.com/
For all the noise around artificial intelligence, the most useful question for a myopia practice isn’t “Will this replace me?” It’s “Can this help me do the work I already know I should be doing?”
That’s the premise of this week’s episode. I sat down with my friend Louise Curcio — a fractional marketing director with a focus on AI-augmented marketing, and formerly the director of myopia management marketing at CooperVision — to walk through a practical list of marketing moves for the myopia practice. None of these are exotic. Most are fundamentals that strong practices have used for years. What’s changed is that AI now makes each one faster, cheaper, and easier to execute, often in the time it takes to listen to this episode.
Contact Louise Curcio on Linkedin
Podcast + Newsletter + Bonus Content on our Substack
Welcome back to Myopia News Monthly, where we cover the top stories in the myopia management industry so you can grow organically into the expert you were always meant to be.
This month’s panel: returning guests Dr. Andrew Brauer, Dr. Cary Herzberg, and Josh Martinez of Doctor’s Own Design/Aurora GP Lab, Inc.
+ SUBSTACK - Full Episodes + Bonus Content + Weekly Articles
This Month’s Stories
1. HHS and the Surgeon General issue a warning on children’s screen use.
2. The FDA rejects Sydnexis’ SYD-101 — despite the STAR trial meeting its primary endpoint.
3. Hoya’s MiYOSMART iQ posts some of the strongest myopia control data ever reported.